Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Venous Thromboembolism 10Venous Thrombosis 7Pulmonary Embolism 7Neoplasms 6Lung Neoplasms 3Thrombosis 2Thromboembolism 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Mesenteric Ischemia 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Warfarin 1Dalteparin 14-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Embolism and Thrombosis × Dalteparin × Clear all
NCT00216866 2017-08-28

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Completed
70 enrolled

Embolism, Thrombosis, Embolism and Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡